Prognostic factors for hyperdiploid-myeloma: Effects of chromosome 13 deletions and IgH translocations

W. J. Chng, R. Santana-Dávila, S. A. Van Wier, G. J. Ahmann, S. M. Jalal, Peter Leif Bergsagel, Marta Chesi, M. C. Trendle, S. Jacobus, E. Blood, M. M. Oken, K. Henderson, R. A. Kyle, Morie Gertz, Martha Lacy, Angela Dispenzieri, P. R. Greipp, Rafael Fonseca

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Chromosomal hyperdiploidy is the defining genetic signature in 40-50% of myeloma (MM) patients. We characterize hyperdiploid-MM (H-MM) in terms of its clinical and prognostic features in a cohort of 220 H-MM patients entered into clinical trials. Hyperdiploid-myeloma is associated with male sex, kappa immunoglobulin subtype, symptomatic bone disease and better survival compared to nonhyperdiploid-MM (median overall survival 48 vs 35 months, log-rank P = 0.023), despite similar response to treatment. Among 108 H-MM cases with FISH studies for common genetic abnormalities, survival is negatively affected by the existence of immunoglobulin heavy chain (IgH) translocations, especially those involving unknown partners, while the presence of chromosome 13 deletion by FISH did not significantly affect survival (median overall survival 50 vs 47 months, log-rank P = 0.47). Hyperdiploid-myeloma is therefore a unique genetic subtype of MM associated with improved outcome with distinct clinical features. The existence of IgH translocations but not chromosome 13 deletion by FISH negatively impacts survival and may allow further risk stratification of this population of MM patients.

Original languageEnglish (US)
Pages (from-to)807-813
Number of pages7
JournalLeukemia
Volume20
Issue number5
DOIs
StatePublished - May 2006

Fingerprint

Chromosomes, Human, Pair 13
Chromosome Deletion
Immunoglobulin Heavy Chains
Polyploidy
Survival
Bone Diseases
Immunoglobulins
Clinical Trials
Population

Keywords

  • Chromosome 13 deletion
  • Hyperdiploid
  • IgH translocations
  • Myeloma
  • Prognosis

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Prognostic factors for hyperdiploid-myeloma : Effects of chromosome 13 deletions and IgH translocations. / Chng, W. J.; Santana-Dávila, R.; Van Wier, S. A.; Ahmann, G. J.; Jalal, S. M.; Bergsagel, Peter Leif; Chesi, Marta; Trendle, M. C.; Jacobus, S.; Blood, E.; Oken, M. M.; Henderson, K.; Kyle, R. A.; Gertz, Morie; Lacy, Martha; Dispenzieri, Angela; Greipp, P. R.; Fonseca, Rafael.

In: Leukemia, Vol. 20, No. 5, 05.2006, p. 807-813.

Research output: Contribution to journalArticle

Chng, WJ, Santana-Dávila, R, Van Wier, SA, Ahmann, GJ, Jalal, SM, Bergsagel, PL, Chesi, M, Trendle, MC, Jacobus, S, Blood, E, Oken, MM, Henderson, K, Kyle, RA, Gertz, M, Lacy, M, Dispenzieri, A, Greipp, PR & Fonseca, R 2006, 'Prognostic factors for hyperdiploid-myeloma: Effects of chromosome 13 deletions and IgH translocations', Leukemia, vol. 20, no. 5, pp. 807-813. https://doi.org/10.1038/sj.leu.2404172
Chng, W. J. ; Santana-Dávila, R. ; Van Wier, S. A. ; Ahmann, G. J. ; Jalal, S. M. ; Bergsagel, Peter Leif ; Chesi, Marta ; Trendle, M. C. ; Jacobus, S. ; Blood, E. ; Oken, M. M. ; Henderson, K. ; Kyle, R. A. ; Gertz, Morie ; Lacy, Martha ; Dispenzieri, Angela ; Greipp, P. R. ; Fonseca, Rafael. / Prognostic factors for hyperdiploid-myeloma : Effects of chromosome 13 deletions and IgH translocations. In: Leukemia. 2006 ; Vol. 20, No. 5. pp. 807-813.
@article{ec3b932e6924490bbf1175aa3c62aac2,
title = "Prognostic factors for hyperdiploid-myeloma: Effects of chromosome 13 deletions and IgH translocations",
abstract = "Chromosomal hyperdiploidy is the defining genetic signature in 40-50{\%} of myeloma (MM) patients. We characterize hyperdiploid-MM (H-MM) in terms of its clinical and prognostic features in a cohort of 220 H-MM patients entered into clinical trials. Hyperdiploid-myeloma is associated with male sex, kappa immunoglobulin subtype, symptomatic bone disease and better survival compared to nonhyperdiploid-MM (median overall survival 48 vs 35 months, log-rank P = 0.023), despite similar response to treatment. Among 108 H-MM cases with FISH studies for common genetic abnormalities, survival is negatively affected by the existence of immunoglobulin heavy chain (IgH) translocations, especially those involving unknown partners, while the presence of chromosome 13 deletion by FISH did not significantly affect survival (median overall survival 50 vs 47 months, log-rank P = 0.47). Hyperdiploid-myeloma is therefore a unique genetic subtype of MM associated with improved outcome with distinct clinical features. The existence of IgH translocations but not chromosome 13 deletion by FISH negatively impacts survival and may allow further risk stratification of this population of MM patients.",
keywords = "Chromosome 13 deletion, Hyperdiploid, IgH translocations, Myeloma, Prognosis",
author = "Chng, {W. J.} and R. Santana-D{\'a}vila and {Van Wier}, {S. A.} and Ahmann, {G. J.} and Jalal, {S. M.} and Bergsagel, {Peter Leif} and Marta Chesi and Trendle, {M. C.} and S. Jacobus and E. Blood and Oken, {M. M.} and K. Henderson and Kyle, {R. A.} and Morie Gertz and Martha Lacy and Angela Dispenzieri and Greipp, {P. R.} and Rafael Fonseca",
year = "2006",
month = "5",
doi = "10.1038/sj.leu.2404172",
language = "English (US)",
volume = "20",
pages = "807--813",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Prognostic factors for hyperdiploid-myeloma

T2 - Effects of chromosome 13 deletions and IgH translocations

AU - Chng, W. J.

AU - Santana-Dávila, R.

AU - Van Wier, S. A.

AU - Ahmann, G. J.

AU - Jalal, S. M.

AU - Bergsagel, Peter Leif

AU - Chesi, Marta

AU - Trendle, M. C.

AU - Jacobus, S.

AU - Blood, E.

AU - Oken, M. M.

AU - Henderson, K.

AU - Kyle, R. A.

AU - Gertz, Morie

AU - Lacy, Martha

AU - Dispenzieri, Angela

AU - Greipp, P. R.

AU - Fonseca, Rafael

PY - 2006/5

Y1 - 2006/5

N2 - Chromosomal hyperdiploidy is the defining genetic signature in 40-50% of myeloma (MM) patients. We characterize hyperdiploid-MM (H-MM) in terms of its clinical and prognostic features in a cohort of 220 H-MM patients entered into clinical trials. Hyperdiploid-myeloma is associated with male sex, kappa immunoglobulin subtype, symptomatic bone disease and better survival compared to nonhyperdiploid-MM (median overall survival 48 vs 35 months, log-rank P = 0.023), despite similar response to treatment. Among 108 H-MM cases with FISH studies for common genetic abnormalities, survival is negatively affected by the existence of immunoglobulin heavy chain (IgH) translocations, especially those involving unknown partners, while the presence of chromosome 13 deletion by FISH did not significantly affect survival (median overall survival 50 vs 47 months, log-rank P = 0.47). Hyperdiploid-myeloma is therefore a unique genetic subtype of MM associated with improved outcome with distinct clinical features. The existence of IgH translocations but not chromosome 13 deletion by FISH negatively impacts survival and may allow further risk stratification of this population of MM patients.

AB - Chromosomal hyperdiploidy is the defining genetic signature in 40-50% of myeloma (MM) patients. We characterize hyperdiploid-MM (H-MM) in terms of its clinical and prognostic features in a cohort of 220 H-MM patients entered into clinical trials. Hyperdiploid-myeloma is associated with male sex, kappa immunoglobulin subtype, symptomatic bone disease and better survival compared to nonhyperdiploid-MM (median overall survival 48 vs 35 months, log-rank P = 0.023), despite similar response to treatment. Among 108 H-MM cases with FISH studies for common genetic abnormalities, survival is negatively affected by the existence of immunoglobulin heavy chain (IgH) translocations, especially those involving unknown partners, while the presence of chromosome 13 deletion by FISH did not significantly affect survival (median overall survival 50 vs 47 months, log-rank P = 0.47). Hyperdiploid-myeloma is therefore a unique genetic subtype of MM associated with improved outcome with distinct clinical features. The existence of IgH translocations but not chromosome 13 deletion by FISH negatively impacts survival and may allow further risk stratification of this population of MM patients.

KW - Chromosome 13 deletion

KW - Hyperdiploid

KW - IgH translocations

KW - Myeloma

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=33646153077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646153077&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2404172

DO - 10.1038/sj.leu.2404172

M3 - Article

C2 - 16511510

AN - SCOPUS:33646153077

VL - 20

SP - 807

EP - 813

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 5

ER -